Figure 4
From: Topical netarsudil for the treatment of primary corneal endothelial degeneration in dogs
No significant differences were observed in CCT measured by USP (A), corneal stromal thickness measured by OCT (B), ECD measured with non-applanation IVCM (C), and percentage of cornea affected by edema (D) in patients treated with netarsudil during 8 months versus patients receiving vehicle control during the first 4 months. Two-way repeated measures ANOVA. Depicted are the mean and the standard deviation. For CCT, USP, percentage of corneal edema: Netarsudil group: baseline, 1, 2 and 4 months: 12 eyes. Six months and 8 months: 11 eyes. Twelve months: 6 eyes. Vehicle group: baseline, 1, 2 and 4 months: 14 eyes. Six months: 13 eyes. Eight months: 12 eyes. Twelve months: 5 eyes. ECD: Netarsudil group: baseline, 1, 2 and 4 months: 12 eyes. Six and 8 months: 11 eyes. Twelve months: 5 eyes. Vehicle group: baseline, 1, 2 and 4 months: 14 eyes. Six months: 13 eyes. Eight months: 12 eyes. Twelve months: 3 eyes.
